TRIPASS XR تري باس

 

146

Eluxadoline is a minimally absorbed µ-opioid receptor agonist and δ-opioid

receptor antagonist. Studies have shown that when there is simultaneous µ-opioid

receptor agonism and δ-opioid receptor antagonism, patients will experience

decreased abdominal pain and diarrhea.

147

The dosage approved for the treatment of IBS-D is 100 mg twice daily taken with

food, but the dose is reduced to 75 mg BID in patients who are unable to tolerate 100

mg BID, have no gallbladder, have mild to moderate liver impairment, or are on

organic anion transporting polypeptides (OATP1B1) inhibitors.

148 Patients treated

with eluxadoline had better clinical response in phase 2 trials with decreased

abdominal pain and increase stool consistency without significant risk of

constipation.

147 The most common side effects in patients treated with eluxadoline

include constipation, nausea, and abdominal pain.

148 The most serious known risk

associated with eluxadoline is the risk of sphincter of Oddi spasm, which can result

in pancreatitis. Eluxadoline should not be used in patients with a history of bile duct

obstruction, pancreatitis, severe liver impairment, or severe constipation, and in

patients who drink more than three alcoholic beverages daily.

148 Patients should be

counseled to avoid alosetron or loperamide in combination with eluxadoline on a

chronic basis, although it can be used on an acute as needed basis. If signs of

constipation occur, the patient must be advised to discontinue loperamide

immediately. They must discontinue eluxadoline if they experience constipation for

more than 4 days. Patients should also be advised to avoid concomitant use of

anticholinergics and other opioids with eluxadoline to avoid constipation. They

should be reminded that eluxadoline has a potential for drug abuse.

148

In L.K.’s case, initiation of loperamide 2 mg as needed before a stressful situation

would be a cost-effective approach to her symptoms. Should her symptoms worsen

or her current regimen lose effectiveness, eluxadoline 100 mg BID with food is an

alternative, while a course of rifaximin 550 mg TID for 14 days would be considered

an alternative strategy if she fails eluxadoline. The patient should be advised not to

combine these therapies for chronic treatment and discontinue eluxadoline if she

experiences constipation for 4 days.

p. 536

p. 537

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Buchner AM et al. Update on the Management of Crohn’s Disease. Curr Gastroeterol Rep. 2011;13:465. (31)

Colombel JF et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med.

2010;362:1383. (74)

Hoentjen F et al. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep. 2011;13:475. (19)

Ford A et al. “American College Gastroenterology Monograph on the Management of Irritable Bowel Syndrome

and Chronic Idiopathic Constipation” Am J Gastroenterol. 2014;109:S2–S26. (114)

Kornbluth A et al. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice

Parameters Committee. Am J Gastroenterol. 2010;105:501. (14)

Lichtenstein GR et al. American Gastroenterological Association Institute technical review on corticosteroids,

immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130: 940. (25)

Lichtenstein GR et al. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465. (16)

Pimentel M et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med.

2011;364: 22. (143)

Regueiro M et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative

proctitis:summary statement. Inflamm Bowel Dis. 2006;12:972. (22)

Talley NJ et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J

Gastroenterol. 2011;106(Suppl 1): S2–25; quiz S26. doi: 10.1038/ajg.2011.58. (3)

COMPLETE REFERENCES CHAPTER 24 LOWER

GASTROINTESTINAL DISORDERS

Abraham C, Cho JH. Inflammatory bowel disease. N EnglJ Med. 2009;361:2066.

Loftus CG et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted

County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254.

Talley NJ et al; American College of Gastroenterology IBD Task Force. An evidence-based systematic review on

medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011:106:S2–S25.

Podolsky DK. Inflammatory bowel disease. N EnglJ Med. 2002;347:417.

Tremaine WJ. Review article: indeterminate colitis—definition, diagnosis and management. Aliment Pharmacol

Ther. 2007;25:13.

Melum E et al. Genome-wide association studies—a summary for the clinical gastroenterologist. World J

Gastroenterol. 2009;15:5377.

Pardi DS et al. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19:355.

Marks DJ et al. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet. 2006;367:668.

Birrenbach T, Bòcker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology,

and therapeutic implications. Inflamm Bowel Dis. 2004;10:848.

Eckburg PB, Relman DA. The role of microbes in Crohn’s disease. Clin Infect Dis. 2007;44:256.

Liu ZJ et al. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J

Gastroenterol. 2009;15:5784.

Bernstein CN et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management

of IBD in 2010. Inflamm Bowel Dis. 2010;16:112.

Carter MJ et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl

5):V1.

Kornbluth A et al. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice

Parameters Committee. Am J Gastroenterol. 2010;105:501.

Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6:616.

Ardizzone S et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40(Suppl

2):S253.

Lichtenstein GR et al. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465.

Sandborn WJ. What’s new: innovative concepts in inflammatory bowel disease. Colorectal Dis. 2006;8(Suppl

1):3.

Hoentjen F et al. Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011;13:475.

Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient

outcomes. Drugs. 2008;68:1089.

Drug Facts and Comparisons 4.0 [on-line] 2010. http://www.wolterskluwercdi.com/facts-comparisonsonline/. Accessed January 27, 2011.

Regueiro M et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative

proctitis:summary statement. Inflamm Bowel Dis. 2006;12:972.

Katz S et al. 5-ASA dose-response: maximizing efficacy and adherence. Gastroenterol Hepatol (NY). 2010;6(2,

Suppl 3):1.

Irving PM et al. Review article: appropriate use of corticosteroids in Crohn’s disease [published correction

appears in Aliment Pharmacol Ther. 2008;27:528]. Aliment Pharmacol Ther. 2007;26:313.

Lichtenstein GR et al. American Gastroenterological Association Institute technical review on corticosteroids,

immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940.

Entocort [product information]. Sodertalje, Sweden: AstraZeneca, Inc; June 2009.

Lichtenstein GR et al. Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis.

Aliment Pharmacol Ther. 2009;29:643.

Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin

Pharmacokinet. 2004;43:803.

Hofer KN. Oral budesonide in the management of Crohn’s disease. Ann Pharmacother. 2003;37:1457.

Kane SV et al. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther.

2002;16:1509.

Buchner AM et al. Update on the Management of Crohn’s Disease. Curr Gastroeterol Rep. 2011;13:465.

Plevy SE. Corticosteroid-sparing treatments in patients with Crohn’s disease. Am J Gastroenterol. 2002;97:1607.

Ardizzone S et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s

disease: a randomised, investigator-blind study. Dig Liver Dis. 2003;35:619.

Terdiman JP et al. Guideline on the use of thiopurines, methotrexate, and Anti-TNF-α biologic drugs for the

induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459.

Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet. 2002;359:331.

Van Assche G et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in

severe ulcerative colitis. Gastroenterology. 2003;125:1025.

Peyrin-Biroulet L et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis

of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644.

Rutgeerts P et al. Infliximab for induction and maintenance therapy for ulcerative colitis [published correction

appears in N EnglJ Med. 2006;354:2200]. N EnglJ Med. 2005;353:2462.

Osterman MT, Lichtenstein GR. Infliximab in fistulizing Crohn’s disease. Gastroenterol Clin North Am.

2006;35:795.

Kaplan GG et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a

cost effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509.

Afif W et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients

with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133.

Epple HJ. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis.

2009;27:555.

Papadakis KA et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated

response to infliximab. Am J Gastroenterol. 2005;100:75.

Rutgeerts P et al. Biological therapies for inflammatory bowel diseases [published correction appears in

Gastroenterology. 2009;136:1844]. Gastroenterology. 2009;136:1182.

Thia KT et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s

disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17–24.

Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr

Opin Gastroenterol. 2009;25:329.

Smith PA. Nutritional therapy for active Crohn’s disease. World J Gastroenterol. 2008;14:4420.

ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and

enteral nutrition in adult and pediatric patients [published correction appears in J Parenter Enteral Nutr.

2002;26:144]. J Parenter Enteral Nutr. 2002;26(1 Suppl):1SA.

Shah SB, Hanauer SB. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions.

Rev Gastroenterol Disord. 2007;7(Suppl 3):S3.

Cohen JL et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum.

2005;48:1997.

Juillerat P et al. Extraintestinal manifestations of Crohn’s disease. Digestion. 2007;76:141.

Hanai H et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med.

2004;13:643.

Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol.

2009;3:395.

Briggs GG et al, eds. Mesalamine. In Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and

Neonatal Risk. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:1506.

Borrelli O et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a

randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744.

Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol. 2002;97:803.

Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment

Pharmacol Ther. 2006;23:841.

Ali T et al. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122:599.

Cino M, Greenberg GR. Bone mineral density in Crohn’s disease: a longitudinalstudy of budesonide, prednisone,

and nonsteroid therapy. Am J Gastroenterol. 2002;97:915.

Lewis NR et al. Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac Disease. London:

British Society of Gastroenterology; 2007. http://www.bsg.org.uk/images/stories/clinical/ost_coe_ibd.pdf.

Accessed April 13, 2011.

Iacucci M et al. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol.

2010;24:127.

Gisbert JP et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic

review. Dig Dis Sci. 2002;47:471.

Velayos FS et al. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and

metaanalysis of observationalstudies. Am J Gastroenterol. 2005;100:1345.

Leung Y et al. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig

Dis Sci. 2008;53:1455.

Holme O et al. Treatment of fulminant ulcerative colitis with cyclosporine A. Scand J Gastroenterol.

2009;44:1310.

Esteve M et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for

primary prophylaxis. Gut. 2004;53:1363.

Melmed GY et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J

Gastroenterol. 2006;101:1834.

Sands BE et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis.

2004;10:677.

Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1158.

van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl.

2006;(243):59.

Gasche C. Complications of inflammatory bowel disease. Hepatogastroenterology. 2000;47:49.

Peyrin-Biroulet L et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J

Gastroenterol. 2010;105:289.

Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double

blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379.

Colombel JF et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med.

2010;362:1383.

ColombelJF et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58(7):940.

Schreiber S et al. Maintenance therapy with certolizumab pegol for Crohn’s disease [published correction appears

in N EnglJ Med. 2007;357:1357]. N EnglJ Med. 2007;357:239.

Sandborn WJ et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med.

2005;353:1912.

Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec; 2013.

Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America; 2014.

Ochenrider MG et al. Hepatosplenic T-cell lymphoma in a young man with Crohn’s disease: case report and

literature review. Clin Lymphoma Myeloma Leuk. 2010;10:144.

Travis SPL. Infliximab and azathioprine: bridge or parachute? Gastroenterology. 2006;130:1354.

Etchevers MJ et al. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory

bowel disease. World J Gastroenterol. 2008;14:5512.

Sahasranaman S et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol.

2008;64:753.

Cuffari C et al. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in

patients with inflammatory bowel disease. Gut. 2001;48:642.

Imuran [package insert]. Prometheus Laboratories Inc: Hunt Valley, MD; 2011.

Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease.

Aliment Pharmacol Ther. 2005;21:307.

Soon SY et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J

Gastroenterol Hepatol. 2004;16:921.

Fraser AG et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment

Pharmacol Ther. 2002;16:693.

Lichtenstein GR et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in

fistulizing Crohn’s disease. Gastroenterology. 2005;128:862.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

Lindsay J et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with

infliximab for Crohn’s disease—modelling outcomes in active luminal and fistulizing disease in adults. Aliment

Pharmacol Ther. 2008;28:76.

Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment

of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19.

Van Assche GV et al. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin

Gastroenterol. 2006;22:370.

Caspersen S et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and

follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212.

Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel

disease. Gut. 2004;53:780.

American College of Gastroenterology Task Force on Irritable Bowel Syndrome et al. An evidence-based

position statement on the management of irritable bowelsyndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1.

Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for

healthcare practitioners. J Gastroenterol Hepatol. 2010;25:691.

Rey E, Talley NJ. Irritable bowelsyndrome: novel views on the epidemiology and potential risk factors. Dig Liver

Dis. 2009;41:772.

Horwitz BJ, Fisher RS. The irritable bowelsyndrome. N EnglJ Med. 2001;344:1846.

Hillila MT et al. Societal costs for irritable bowel syndrome—a population based study. Scand J Gastroenterol.